RLAY · NASDAQ · STOCK
Relay Therapeutics (RLAY) Stock Analysis
$18.85
52W $4.05 – $21.27
61/100
$4.16B
-12.1
1.70
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is RLAY Bullish or Bearish?
Bullish.
Innellis AI committee rates Relay Therapeutics, Inc. (RLAY) Buy with a composite score of 61/100
, based on 6 analysts with 50% agreement.
Last updated September 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.78 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.22 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.25 across 4 articles, 14d) — News
Bear Case
- ROE of only -42.3% -- cheap may mean cheap for a reason — Value
- 2 consecutive earnings misses -- execution concerns — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 17, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 29%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -42.3% -- cheap may mean cheap for a reason
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Investment Thesis Evolution
Committee score moved marginally from 61.2 to 61.2.
Comparing 2026-09-16 to 2026-09-17 (1 day apart).
Technical Analysis
RSI (14)
47.8
Neutral
MACD Histogram
-0.044
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$11.62
Resistance
$20.79
Bollinger %B
0.40
Inside Bands
Price vs Moving Averages
EMA 9
$18.97
Below
EMA 21
$19.13
Below
EMA 50
$18.74
Above
EMA 200
$14.18
Above
Fundamental Analysis
Valuation
86
Growth
65
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-12.1×
P/B Ratio
4.32×
PEG Ratio
-0.55
Dividend Yield
0.00%
52W High
$21.27
52W Low
$4.05
Quality & Growth
ROE
-4875.7%
ROA
-4449.8%
Gross Margin
—
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
P/E ratio of -12.1 (inexpensive relative to a 15-40x range); Price-to-book of 4.3x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -48.8%; Return on assets of -44.5%; Net margin of -2763.6%; Gross margin of -566.6%; Current ratio of 18.27 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-1.05); Most recent quarter missed estimates by 2.8%; 2 consecutive earnings misses; EPS growth accelerating (-28.1% -> +0.0% QoQ); Analyst estimates rising over recent quarters
Get the Full RLAY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →